|

Roles of Hepatic Insufficiency, Hepatic Fibrosis, and Inorganic Pyrophosphate in the Progression of Arterial Calcifications

RECRUITINGN/ASponsored by Centre Hospitalier Universitaire de Nice
Actively Recruiting
PhaseN/A
SponsorCentre Hospitalier Universitaire de Nice
Started2025-11-24
Est. completion2028-11-24
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07201649

Summary

Individuals with metabolic syndrome (MetS), particularly those with type 2 diabetes (T2D), and/or metabolic dysfunction-associated steatohepatitis or MASH face an elevated risk of major cardiovascular events (MACE). We showed decrease plams level of PPi in patients with liver cirrhosis. We hypothezised that liver transplant should block AC and restore PPi plasma level.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* everyone requiring liver transplantation for the treatment of a chronic liver disease

Exclusion Criteria:

* MELD score \>25, viral replication

Conditions2

Liver CirrhosisLiver Disease

Browse More Trials

Liver Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.